Satish Mishra
Cardiovascular Disease · Houston, TXNPI 1760975403
Payments from drug & device makers
Across 144 payments — averaging $49.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heartflow, Inc.$2K
- Abbott$1K
- Novartis$551
- AstraZeneca$483
- Boston Scientific$318
- Amgen$305
- plus $2K from 20 others
What the payments were for
- Travel & lodging$1,57722%
- Food & beverage$5,18572%
- Education$3935%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Heartflow, Inc. | 13 | $1,667 |
| Abbott | 22 | $1,366 |
| Novartis | 26 | $551 |
| AstraZeneca | 12 | $483 |
| Boston Scientific | 8 | $318 |
| Amgen | 5 | $305 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $299 |
| Edwards Lifesciences | 3 | $224 |
| Sanofi-aventis U.S. LLC | 2 | $208 |
| AbbVie | 2 | $181 |
| Johnson & Johnson | 3 | $181 |
| Medtronic | 7 | $153 |
| Boehringer Ingelheim | 3 | $151 |
| E.r. Squibb & Sons, L.L.C. | 7 | $142 |
| Abiomed | 2 | $133 |
| Livanova USA, Inc. | 2 | $115 |
| Esperion Therapeutics, Inc. | 1 | $101 |
| Siemens Medical Solutions USA, Inc. | 2 | $100 |
| ZOLL Circulation Inc | 1 | $94 |
| Chiesi USA, Inc. | 2 | $90 |
| Merck | 4 | $85 |
| Actelion Pharmaceuticals US, Inc. | 2 | $70 |
| Terumo Medical Corporation | 2 | $46 |
| Teleflex LLC | 2 | $37 |
| Shockwave Medical, Inc | 1 | $28 |
| Pfizer | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$1,480
- TRICLIP$589
- FARXIGA$249
- Repatha$245
- ENSITE$145
- Diamondback Coronary$136
- WATCHMAN Access System$129
- XARELTO$125
- DRAGONFLY OPSTAR$125
- BRILINTA$105
- NEXLETOL$101
How this compares
$7,155 in reported general payments places this provider in the 60th percentile of 1,515 cardiovascular disease providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 11 | $8,184 |
| Lisinopril | 12 | $62 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $151 | $8,18411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Houston
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- James FeldmanHouston$3.1M
- Aditya SamalHouston$2.6M
- Pranav LoyalkaHouston$2.4M
- Anwar AhmadHouston$1.4M
- Reynolds DelgadoHouston$1.1M
- Richard SmallingHouston$908K
- Amin KarimHouston$853K
- Stephen LittleHouston$806K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.